

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG439 Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

Lipoatrophy is more common in Caucasians.

All people with HIV infection are covered by the Disability Discrimination Act.

Women are at higher risk than men.

Patients with HIV may have associated disabilities covered by disability legislation.

Issues related to sexual orientation are covered under equalities legislation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?

Potential questions of equalities relating to disability and sexual orientation were thought to have an impact on the assessment of the procedure.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality

issues?
No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?
Yes, The Committee had a comment in 2.5 relating to disability.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?
No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?
No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?
No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?

Yes, The Committee had a comment in 2.5.1 relating to disability.

Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so,

where?

Yes, The Committee had a comment in 2.5.1 relating to disability.

Approved by Associate Director

Date: 28/11/2012